Establishment Labs (ESTA) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
24 Feb, 2026Executive summary
Q4 2025 revenue reached $64.6 million, up 45.2% year-over-year, with US Motiva revenue at $17.3 million and full-year revenue at $211.1 million, a 27.2% increase over 2024.
Operational leverage improved, with gross margin exceeding 70% for the second consecutive quarter.
Adjusted EBITDA turned positive at $5.5 million in Q4, compared to a loss of $13.1 million in Q4 2024.
Net loss from operations for Q4 was $3.9 million, a 79% reduction from the prior year.
Ended 2025 with $75.6 million in cash and no need for additional capital.
Financial highlights
Gross profit for Q4 was $45.5 million (70.5% margin), up from $30.5 million (68.5% margin) in Q4 2024.
SG&A expenses were flat at $44.0 million in Q4; total operating expenses were $49.5 million.
R&D expenses rose slightly to $5.4 million due to personnel and regulatory costs.
Full-year net loss was $51.1 million, improved from $84.6 million in 2024.
Cash increased by $4.9 million in Q4, primarily from reduced operating cash use and option exercises.
Outlook and guidance
2026 revenue guidance is $264–$266 million, representing 25%+ growth over 2025.
2027 revenue growth is projected to be at least 25%.
US expected to exceed 30% of overall sales in 2026, up from 22% in 2025.
Gross margins projected to rise by 200–300 basis points in 2026.
Free cash use in 2026 to be less than half of 2025; company expects to be cash flow positive in 2026.
Latest events from Establishment Labs
- Motiva's U.S. growth outpaced expectations, with premium pricing and innovation fueling expansion.ESTA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Q2 revenue rose 18.7% sequentially; FDA approval for Motiva Implants expected soon.ESTA
Q2 20242 Feb 2026 - Innovation, global expansion, and regulatory progress position the company for rapid growth.ESTA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - U.S. approval nears as global expansion and premium product launches drive margin growth.ESTA
Jefferies Global Healthcare Conference31 Jan 2026 - US market share surges with FDA-approved, innovative implants and strong financial momentum.ESTA
44th Annual J.P. Morgan Healthcare Conference30 Jan 2026 - Q3 revenue grew, losses narrowed, and U.S. Motiva launch plus new funding boosted outlook.ESTA
Q3 202415 Jan 2026 - FDA approval and U.S. launch drive growth outlook, with 2025 set as a transformative year.ESTA
UBS Global Healthcare Conference14 Jan 2026 - Premium innovation and global expansion fuel growth, with profitability targeted by 2026.ESTA
Jefferies London Healthcare Conference 202413 Jan 2026 - Rapid U.S. expansion and product innovation position the company for strong growth and market share gains.ESTA
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026